ADXN (Addex) רווח למניה ב-12 החודשים האחרונים

Addex Therapeutics (ADXN) plans to generate revenue by bringing oral therapies for Parkinson's disease into commercial circulation. Development relies on a system of allosteric modulators that allows for the precise adjustment of brain function. This chart of the rolling annual EPS growth visualizes the fundamental stability of the business, where -3.70 determines the current status of the parameter. Currently, the company lacks pricing power due to the absence of stable revenue.

Addex Therapeutics focuses on developing small molecules for the therapy of neurological pathologies, securing funding through grants and partnerships. This EPS YoY TTM trend captures the annual change in net income per share over the last twelve months. This indicator measures the efficiency of intellectual property capitalization and the growth rate of returns. The stability of these metrics within the channel confirms the transparency of financial accounting. Sharp fluctuations in the chart signal a revaluation of the cost of capital following changes in the terms of partnership agreements.